Fintel on MSN1d
Raymond James Initiates Coverage of Erasca (ERAS) with Outperform Recommendation
Fintel reports that on March 26, 2025, Raymond James initiated coverage of Erasca (NasdaqGS:ERAS) with a Outperform ...
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Medscape7d
Clinical Overview of Sorafenib in Breast Cancer
Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...
Quanta Therapeutics Announces Late-Breaking Presentation of QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025
Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...
Frontiers8d
Targeting Cellular Signalling Pathways for Disease Therapy: The Potential of Cellular Reprogramming and Protein Kinase Inhibitors
Cellular reprogramming is an intrinsic evolutionary trait to constantly promote adaptations that confer survival advantage.
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001Erasca will also present ...